Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fescharek

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Vaccine|April 1, 1990
Dangers of immunosuppressive treatments in postexposure rabies prophylaxisR Fescharek, V Franke
BMJ (Clinical Research Ed.)|December 16, 1995
Transverse myelitis unlikely to be due to measles, mumps, and rubella vaccineR Fescharek, H Dass
BMJ (Clinical Research Ed.)|December 3, 1994
Skin necrosis induced by streptokinaseH Dass, R Fescharek
Vaccine|August 1, 1990
Postexposure rabies vaccination during pregnancy: experience from post-marketing surveillance with 16 patientsR Fescharek, U Quast, G Dechert
Vaccine|November 19, 1997
OPV vs IPV--could placental immunity reduce the number of vaccine-associated paralytic poliomyelitis?R Fescharek, R K Budde, C Arras
Vaccine|January 1, 1994
Do anaesthetics and surgical stress increase the risk of post-exposure rabies treatment failure?R Fescharek, V Franke, M R Samuel
Developments in Biological Standardization|December 17, 1998
Monitoring and safety assessment in Phase I to III clinical trialsR Fescharek, U Nicolay, C Arras-Reiter
Lancet (London, England)|May 11, 1996
Do specific hyperimmunoglobulins aggravate clinical course of tick-borne encephalitis?C Arras, R Fescharek, J P Gregersen
Statistics in Medicine|December 30, 1993
Alert systems for post-marketing surveillance of adverse drug reactionsM Praus, F Schindel, R Fescharek, et al.
Vaccine|October 1, 1990
Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effectsR Fescharek, U Quast, G Maass, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Vaccine|April 1, 1990
Dangers of immunosuppressive treatments in postexposure rabies prophylaxisR Fescharek, V Franke
BMJ (Clinical Research Ed.)|December 16, 1995
Transverse myelitis unlikely to be due to measles, mumps, and rubella vaccineR Fescharek, H Dass
BMJ (Clinical Research Ed.)|December 3, 1994
Skin necrosis induced by streptokinaseH Dass, R Fescharek
Vaccine|August 1, 1990
Postexposure rabies vaccination during pregnancy: experience from post-marketing surveillance with 16 patientsR Fescharek, U Quast, G Dechert
Vaccine|November 19, 1997
OPV vs IPV--could placental immunity reduce the number of vaccine-associated paralytic poliomyelitis?R Fescharek, R K Budde, C Arras
Vaccine|January 1, 1994
Do anaesthetics and surgical stress increase the risk of post-exposure rabies treatment failure?R Fescharek, V Franke, M R Samuel
Developments in Biological Standardization|December 17, 1998
Monitoring and safety assessment in Phase I to III clinical trialsR Fescharek, U Nicolay, C Arras-Reiter
Lancet (London, England)|May 11, 1996
Do specific hyperimmunoglobulins aggravate clinical course of tick-borne encephalitis?C Arras, R Fescharek, J P Gregersen
Statistics in Medicine|December 30, 1993
Alert systems for post-marketing surveillance of adverse drug reactionsM Praus, F Schindel, R Fescharek, et al.
Vaccine|October 1, 1990
Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effectsR Fescharek, U Quast, G Maass, et al.
Pageof 2